Display Settings:

Format

Send to:

Choose Destination
    J Infect Dis. 2001 Feb 15;183(4):563-70. Epub 2001 Jan 18.

    Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

    Abstract

    Elicitation of both memory cytotoxic T cell responses and human immunodeficiency virus (HIV)-neutralizing antibodies are desirable characteristics of an HIV vaccine regimen. We studied a combination vaccine regimen consisting of a canarypox (CP) vector containing Env, Gag, and Pro, in combination with a recombinant gp120 subunit protein. Twenty-six of 42 subjects who received CP Vac-Env-Pro demonstrated in vitro CD8(+) T cell responses, versus 3 of 17 who received the control CP rabies or gp120 vaccine only (P=.0003); 15 of these 26 demonstrated a CD8(+) cytotoxic T lymphocyte (CTL) response on > or =2 occasions postvaccination. The frequency of CD8(+) CTL response to HIV antigens was similar between vaccinia-naive and vaccinia-immune persons. Rgp120 immunization did not increase the CD8(+) CTL response to HIV type 1 envelope proteins, but rgp120 boosting did markedly enhance the titer and frequency of neutralizing antibodies to the MN strain of HIV. Overall, the combination of a CP Gag, Pro, Env vector, in combination with recombinant gp120, resulted in neutralizing antibodies in 91% of subjects and CD8(+) T cell responses in 62% of subjects. A nonreplicating pox virus shuttle vector vaccine appears to be capable of eliciting CD8(+) CTL responses in most healthy volunteers, whether they were vaccinia naive or vaccinia immune.

    PMID:
    11170981
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk